Screener
BridgeBio Pharma BBIO Accrued rebates and other related costs
Accrued rebates and other related costs at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept bbio:AccruedRebatesAndOtherRelatedCostsCurrent.
The source filing: BridgeBio Pharma’s 10-Q, filed August 10, 2026.
- Filed
- Aug 10, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001743881-26-000027
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accrued rebates and other related costs | $79,967 | $45,909 |
| Accrued commercial | 52,167 | 35,773 |
| Deferred royalty obligations, current portion (1) | 29,283 | 11,221 |
| Accrued interest | 16,532 | 14,411 |
| Accrued professional services | 7,778 | 3,665 |
| Other accrued liabilities | 6,459 | 9,243 |
| Total other current liabilities | $192,186 | $120,222 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's accrued rebates and other related costs?
- BridgeBio Pharma (BBIO) reported accrued rebates and other related costs of $79.97M in Q2 2026.
- What does accrued rebates and other related costs mean?
- Accrued rebates and other related costs as reported by BridgeBio Pharma, Inc. Common Stock.
Ask your AI about BridgeBio Pharma's accrued rebates and other related costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude